Advanced search
Publication Cover
Leukemia & Lymphoma Volume 43, 2002 - Issue 1
Submit an article Journal homepage
108
Views
50
CrossRef citations to date
0
Altmetric
Research Article

Treatment of Refractory Peripheral T-cell Lymphoma with Denileukin Diftitox (ONTAK ® )

Rakhshandra Talpur Division of Internal Medical Specialties, Department of Dermatology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4095, USA
,
Narin Apisarnthanarax Division of Internal Medical Specialties, Department of Dermatology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4095, USA
,
Staci Ward Division of Internal Medical Specialties, Department of Dermatology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4095, USA
&
Madeleine Duvic Division of Internal Medical Specialties, Department of Dermatology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4095, USA
Pages 121-126 | Published online: 01 Jul 2009

Citations (50)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (8)

H. Miles Prince, Ann G. Martin, Elise A. Olsen, David P. Fivenson & Madeleine Duvic. (2013) Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome. Leukemia & Lymphoma 54:1, pages 69-75.
Read now
Christian SchüTzinger, Harald Esterbauer, Gregor Hron, Cathrin Skrabs, Martin Uffmann, Markus Raderer, Alexander Hauswirth, Christine Mannhalter, Karin Dieckmann, Oswald Wagner, Michael Formanek, Anton Stift, Josef Friedl, Alexander Gaiger, Andreas Chott & Ulrich Jäger. (2008) Prognostic value of T-cell receptor γ rearrangement in peripheral blood or bone marrow of patients with peripheral T-cell lymphomas. Leukemia & Lymphoma 49:2, pages 237-246.
Read now
Bryan Y. Wong, Stephanie A. Gregory & Nam H. Dang. (2007) Denileukin Diftitox as Novel Targeted Therapy for Lymphoid Malignancies. Cancer Investigation 25:6, pages 495-501.
Read now
Kristel Polder, Chiyu Wang, Madeleine Duvic, Abdul H. Diwan, Donald Parks, Aleksandar Jankov, Pamela L. Walker, Ann T. Tong, Joan Bull & Nam H. Dang. (2005) Toxic epidermal necrolysis associated with denileukin diftitox (DAB389IL-2) administration in a patient with follicular large cell lymphoma. Leukemia & Lymphoma 46:12, pages 1807-1811.
Read now
Robert J Kreitman. (2004) Recombinant immunotoxins for the treatment of haematological malignancies. Expert Opinion on Biological Therapy 4:7, pages 1115-1128.
Read now
Uwe Trefzer, Maja Hofmann, Wolfram Sterry & Khusru Asadullah. (2003) Cytokine and anticytokine therapy in dermatology. Expert Opinion on Biological Therapy 3:5, pages 733-743.
Read now
Arthur E Frankel, Donald R Fleming, Bayard L Powell & Ronald Gartenhaus. (2003) DAB389IL2 (ONTAK®) fusion protein therapy of chronic lymphocytic leukaemia. Expert Opinion on Biological Therapy 3:1, pages 179-186.
Read now
Robert J Kreitman. (2002) Recombinant fusion toxins for cancer treatment. Expert Opinion on Biological Therapy 2:8, pages 785-791.
Read now

Articles from other publishers (42)

Yuanchao Jia, Yuxin Jiang, Yonglong He, Wanting Zhang, Jiahui Zou, Kosheli Thapa Magar, Hamza Boucetta, Chao Teng & Wei He. (2023) Approved Nanomedicine against Diseases. Pharmaceutics 15:3, pages 774.
Crossref
Robert C. BastJrJr & Michael R. Zalutsky. 2017. Holland‐Frei Cancer Medicine. Holland‐Frei Cancer Medicine 1 31 .
Robert C. BastJr.Jr., Michael R. Zalutsky & Arthur E. Frankel. 2016. Holland‐Frei Cancer Medicine. Holland‐Frei Cancer Medicine 1 23 .
Prashant Kapoor. 2017. Biology and Management of Unusual Plasma Cell Dyscrasias. Biology and Management of Unusual Plasma Cell Dyscrasias 143 161 .
Madeleine Duvic. (2015) Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome. Hematology 2015:1, pages 529-544.
Crossref
Jia Wei, Jinhuan Xu, Yang Cao, Jianfeng Zhou & Yicheng Zhang. (2015) Allogeneic Stem-Cell Transplantation for Peripheral T-Cell Lymphoma: A Systemic Review and Meta-Analysis. Acta Haematologica 133:2, pages 136-144.
Crossref
Madeleine Duvic. 2013. Lymphoma. Lymphoma 287 329 .
S. I. Romaniuk, D. V. Kolybo & S. V. Komisarenko. (2012) Recombinant diphtheria toxin derivatives: Perspectives of application. Russian Journal of Bioorganic Chemistry 38:6, pages 565-577.
Crossref
Yohei Yamada, Akihiro Aoyama, Georges Tocco, Svjetlan Boskovic, Ognjenka Nadazdin, Alessandro Alessandrini, Joren C. Madsen, A. Benedict Cosimi, Gilles Benichou & Tatsuo Kawai. (2012) Differential Effects of Denileukin Diftitox IL-2 Immunotoxin on NK and Regulatory T Cells in Nonhuman Primates. The Journal of Immunology 188:12, pages 6063-6070.
Crossref
Rakhshandra Talpur & Madeleine Duvic. (2012) Pilot Study of Denileukin Diftitox Alternate Dosing Regimen in Patients With Cutaneous Peripheral T-Cell Lymphomas. Clinical Lymphoma Myeloma and Leukemia 12:3, pages 180-185.
Crossref
Maher Abdul-Hay & Jasmine Zain. (2012) Peripheral T-cell lymphoma: pharmacotherapy overview. Clinical Investigation 2:4, pages 403-416.
Crossref
Claire E. Dearden, Rod Johnson, Ruth Pettengell, Stephen Devereux, Kate Cwynarski, Sean Whittaker & Andrew McMillan. (2011) Guidelines for the management of mature T‐cell and NK‐cell neoplasms (excluding cutaneous T‐cell lymphoma). British Journal of Haematology 153:4, pages 451-485.
Crossref
Prashant Kapoor, Patricia T. Greipp, Eric W. Schaefer, Sumithra J. Mandrekar, Arif H. Kamal, Natalia C. Gonzalez-Paz, Shaji Kumar & Philip R. Greipp. (2010) Idiopathic Systemic Capillary Leak Syndrome (Clarkson's Disease): The Mayo Clinic Experience. Mayo Clinic Proceedings 85:10, pages 905-912.
Crossref
Francesco D’Amore, John Radford, Thomas Relander, Mats Jerkeman, Hervé Tilly, Anders Österborg, Franck Morschhauser, Martin Gramatzki, Martin Dreyling, Bo Bang & Hans Hagberg. (2010) Phase II trial of zanolimumab (HuMax‐CD4) in relapsed or refractory non‐cutaneous peripheral T cell lymphoma. British Journal of Haematology 150:5, pages 565-573.
Crossref
Jasmine M. Zain & Owen O’Connor. (2010) Targeted treatment and new agents in peripheral T-cell lymphoma. International Journal of Hematology 92:1, pages 33-44.
Crossref
C Bachran, A Weng, D Bachran, SB Riese, N Schellmann, MF Melzig & H Fuchs. (2010) The distribution of saponins in vivo affects their synergy with chimeric toxins against tumours expressing human epidermal growth factor receptors in mice. British Journal of Pharmacology 159:2, pages 345-352.
Crossref
Charalampia KyriakouCarmen CanalsJürgen FinkeGuido KobbeJean-Luc HarousseauHans-Jochem KolbNicolas NovitzkyAnthony H. GoldstoneAnna SuredaNorbert Schmitz. (2009) Allogeneic Stem Cell Transplantation Is Able to Induce Long-Term Remissions in Angioimmunoblastic T-Cell Lymphoma: A Retrospective Study From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology 27:24, pages 3951-3958.
Crossref
Bruce D Cheson. (2009) Novel therapies for peripheral T-cell non-Hodgkinʼs lymphomas. Current Opinion in Hematology 16:4, pages 299-305.
Crossref
Robert J. Kreitman. (2009) Recombinant Immunotoxins Containing Truncated Bacterial Toxins for the Treatment of Hematologic Malignancies. BioDrugs 23:1, pages 1-13.
Crossref
Arthur E. Frankel, Jung-Hee Woo & David M. Neville. 2009. Principles of Cancer Biotherapy. Principles of Cancer Biotherapy 407 449 .
Madeleine DuvicRakhshandra Talpur. (2008) Optimizing denileukin diftitox (Ontak ® ) therapy . Future Oncology 4:4, pages 457-469.
Crossref
Steven Le GouillNoel MilpiedAgnès BuzynRégis Peffault De LatourJean-Paul VernantMohamad MohtyMarie-Pierre MolesKrimo BouabdallahClaude-Eric BulaboisJehan DupuisBernard RioNicole GratecosIbrahim Yakoub-AghaMichel AttalOlivier TournilhacDidier DecaudinJean-Henry BourhisDidier BlaiseChristelle VolteauMauricette Michallet. (2008) Graft-Versus-Lymphoma Effect for Aggressive T-Cell Lymphomas in Adults: A Study by the Société Française de Greffe de Moëlle et de Thérapie Cellulaire. Journal of Clinical Oncology 26:14, pages 2264-2271.
Crossref
Kelley Vidulich, Dan Jones & Madeleine Duvic. (2008) Cutaneous γ/δ T-Cell Lymphoma Treated with Radiation and Denileukin Diftitox. Clinical Lymphoma and Myeloma 8:1, pages 55-58.
Crossref
Bruce D. Cheson. (2007) Clinical Management of T-Cell Malignancies: Current Perspectives, Key Issues, and Emerging Therapies. Seminars in Oncology 34, pages S3-S7.
Crossref
S D Smith, B J Bolwell, L A Rybicki, S Brown, R Dean, M Kalaycio, R Sobecks, S Andresen, E D Hsi, B Pohlman & J W Sweetenham. (2007) Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. Bone Marrow Transplantation 40:3, pages 239-243.
Crossref
Amit W. Panwalkar & James O. Armitage. (2007) T-cell/NK-cell lymphomas: A review. Cancer Letters 253:1, pages 1-13.
Crossref
Nam H. Dang, Barbara Pro, Fredrick B. Hagemeister, Felipe Samaniego, Dan Jones, Barry I. Samuels, Maria A. Rodriguez, Andre Goy, Jorge E. Romaguera, Peter McLaughlin, Ann T. Tong, Francesco Turturro, Pamela L. Walker & Luis Fayad. (2007) Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. British Journal of Haematology 136:3, pages 439-447.
Crossref
J. T. Sandlund. 2007. Pediatric Lymphomas. Pediatric Lymphomas 199 213 .
Anatoli Freiman & Denis Sasseville. (2016) Treatment of Mycosis Fungoides: Overview. Journal of Cutaneous Medicine and Surgery 10:5, pages 228-233.
Crossref
Robert J. Kreitman. (2006) Immunotoxins for targeted cancer therapy. The AAPS Journal 8:3, pages E532-E551.
Crossref
Mujahid A. RizviAndrew M. EvensMartin S. TallmanBeverly P. NelsonSteven T. Rosen. (2006) T-cell non-Hodgkin lymphoma. Blood 107:4, pages 1255-1264.
Crossref
John P. Greer. (2006) Therapy of Peripheral T/NK Neoplasms. Hematology 2006:1, pages 331-337.
Crossref
Andrew M. Evens, Christiane Querfeld & Steven T. Rosen. 2006. Hodgkin’s and Non-Hodgkin’s Lymphoma. Hodgkin’s and Non-Hodgkin’s Lymphoma 161 220 .
Mitchell S. Cairo, Elizabeth Raetz, Megan S. Lim, Virginia Davenport & Sherrie L. Perkins. (2005) Childhood and adolescent non-Hodgkin lymphoma: New insights in biology and critical challenges for the future. Pediatric Blood & Cancer 45:6, pages 753-769.
Crossref
Nam H. Dang, Fredrick B. Hagemeister, Barbara Pro, Peter McLaughlin, Jorge E. Romaguera, Dan Jones, Barry Samuels, Felipe Samaniego, Anas Younes, Michael Wang, Andre Goy, Maria A. Rodriguez, Pamela L. Walker, Yolanda Arredondo, Ann T. Tong & Luis Fayad. (2004) Phase II Study of Denileukin Diftitox for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma. Journal of Clinical Oncology 22:20, pages 4095-4102.
Crossref
Dan Jones, Sherif Ibrahim, Kaushali Patel, Rajyalakshmi Luthra, Madeleine Duvic & L. Jeffrey Medeiros. (2004) Degree of CD25 Expression in T-Cell Lymphoma Is Dependent on Tissue Site. Clinical Cancer Research 10:16, pages 5587-5594.
Crossref
Andrew M. Evens & Ronald B. Gartenhaus. (2004) Treatment of T-cell non-hodgkin’ lymphoma. Current Treatment Options in Oncology 5:4, pages 289-303.
Crossref
Richard L. PiekarzRobert W. RobeyZhirong ZhanGanesh KayasthaAnousheh SayahAmina H. AbdeldaimSonia TorricoSusan E. Bates. (2004) T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 103:12, pages 4636-4643.
Crossref
David J. FitzGerald, Robert Kreitman, Wyndham Wilson, David Squires & Ira Pastan. (2004) Recombinant immunotoxins for treating cancer. International Journal of Medical Microbiology 293:7-8, pages 577-582.
Crossref
Arthur E. Frankel, David M. Neville, Thomas A. Bugge, Robert J. Kreitman & Stephen H. Leppla. (2003) Immunotoxin therapy of hematologic malignancies. Seminars in Oncology 30:4, pages 545-557.
Crossref
Arthur E. Frankel, Robert J. Kreitman, Ira Pastan & John R. Murphy. 2003. Principles of Cancer Biotherapy. Principles of Cancer Biotherapy 391 433 .
. (2002) Current Awareness in Hematological Oncology. Hematological Oncology 20:4, pages 189-196.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.